Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States.
Center for Immunotherapy Research, Cancer Center of Excellence, Houston Methodist Research Institute, Houston, TX, United States; Texas A&M College of Medicine, Bryan, TX, United States.
Cell Immunol. 2021 Apr;362:104300. doi: 10.1016/j.cellimm.2021.104300. Epub 2021 Feb 4.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which have been characterized for their immunosuppressive capacity through multiple mechanisms. These cells have been extensively studied in the field of tumor immunity. Emerging evidence has highlighted its essential role in maintaining immune tolerance in transplantation and autoimmunity. Because of their robust immune inhibitory activities, there has been growing interest in MDSC-based cellular therapy. Various pre-clinical studies have demonstrated that the adoptive transfer of MDCS represented a promising therapeutic strategy for immune-related disorders. In this review, we summarize relevant studies of MDSC-based cell therapy in transplantation and autoimmune diseases and discuss the challenges and future directions for clinical application of MDSC-based cell therapy.
髓系来源的抑制性细胞（MDSCs）是一群异质性的未成熟髓系细胞，其通过多种机制表现出免疫抑制能力。这些细胞在肿瘤免疫领域得到了广泛研究。新出现的证据强调了其在移植和自身免疫中维持免疫耐受的重要作用。由于其强大的免疫抑制活性，基于 MDSC 的细胞治疗越来越受到关注。各种临床前研究表明，MDSC 的过继转移代表了一种有前途的免疫相关疾病治疗策略。在这篇综述中，我们总结了基于 MDSC 的细胞治疗在移植和自身免疫性疾病中的相关研究，并讨论了基于 MDSC 的细胞治疗临床应用的挑战和未来方向。
